Results 41 to 50 of about 67,755 (267)

JAK2V617F mutation in a patient with B-cell chronic lymphocytic leukemia and prefibrotic primary myelofibrosis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2015
Introduction. Secondary malignancies, particularly solid tumors, are common in patients with chronic lymphocytic leukemia (CLL), but association of myeloproliferative neoplasms and chronic lymphocytic leukemia in the same patient is very rare ...
Ristić Slobodan, Radojković Milica, Kostić Tatjana, Spasovski Vesna, Pavlović Sonja, Čemerikić-Martinović Vesna   +5 more
doaj   +1 more source

Biofilm‐Binding Phages Enhance Biofilm Eradication by Synergistic Photothermal and Photodynamic Therapy

Advanced Science, EarlyView.
Engineered phage‐based trifunctional nanofibers are developed for synergistic biofilm eradication. Biofilm‐binding phages, armed with AuNPs and TCPP, serve as both warheads and scaffolds, endowing the phototherapy agents with biofilm‐anchoring ability. Upon light irradiation, AuNPs induce photothermal therapy, while TCPP generates 1O2 for photodynamic ...
Ying Cao, Tao Yang, Rui Wang, Hui‐Da Li, Xiao‐Yu Zhang, Feng Cheng, Ying Liu, Jian‐Hua Wang, Ting Yang, Chuanbin Mao   +9 more
wiley   +1 more source

CLINICO-PATHOLOGICAL FEATURES IN PATIENTS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH DEL 11q22

Pakistan Armed Forces Medical Journal, 2020
Objective: To determine the frequency of DEL 11q22 in patients of Chronic Lymphocytic Leukemia and clinico-pathological features in Chronic Lymphocytic Leukemia with DEL 11q22. Study Design: Cross sectional analytical study.
Saqib Hussain Korejo, Chaudhary Altaf, Hamid Saeed Malik, Rafia Mahmood, Ayesha Khurshid, Ali Ahmed   +5 more
doaj   +2 more sources

ZAP-70 expression is associated with increased CD4 central memory T cells in chronic lymphocytic leukemia: cross-sectional study

Hematology, Transfusion and Cell Therapy, 2018
Background: Although chronic lymphocytic leukemia is basically a B cell disease, its pathophysiology and evolution are thought to be significantly influenced by T cells, as these are probably the most important interaction partner of neoplastic B cells ...
Rodolfo Patussi Correia, Flávia Amoroso Matos e Silva, Nydia Strachman Bacal, Paulo Vidal Campregher, Nelson Hamerschlak, Gustavo Pessini Amarante-Mendes   +5 more
doaj   +1 more source

Penfluridol Triggers GSDME‐Mediated Immunogenic Pyroptosis to Potentiate Antitumor Immunotherapy

Advanced Science, EarlyView.
A high‐throughput screen of FDA‐approved antipsychotics identifies penfluridol as a potent pyroptosis inducer acting via direct TTI1 inhibition. This triggers TNFA‐NFKB signaling and caspase‐8/‐3‐dependent GSDME cleavage. The compound stimulates antitumor immunity alone and synergizes with anti‐PD‐1 therapy, while low TTI1 expression emerges as a ...
Linfeng Li, Daishi Li, Danyao Chen, Yating Dian, Lei Yao, Hui Su, Ziyu Guo, Deze Zhao, Zihua Wu, Furong Zeng, Chunfang Zhang, Guangtong Deng   +11 more
wiley   +1 more source

Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group

Haematologica, 2011
Background Optimal lymphocyte parameters and thresholds for the diagnosis of chronic lymphocytic leukemia have been proposed by The National Cancer Institute sponsored Working Group and recently updated by the International Workshop on chronic ...
Stefano Molica, Francesca R. Mauro, Diana Giannarelli, Francesco Lauria, Agostino Cortelezzi, Maura Brugiatelli, Vincenzo Liso, Antonio Cuneo, Robin Foà   +8 more
doaj   +1 more source

Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance

Advanced Science, EarlyView.
Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Jonas Aufdermauer, Ian de Ridder, Mahjoobeh Ehsani, Marasim Khan, Justin Kale, Lukas P. Frenzel, David Andrews, Spyridoula Karamanou, Ana J. Garcia‐Saez, Geert Bultynck   +9 more
wiley   +1 more source

The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia

Haematologica, 2013
Chronic lymphocytic leukemia is marked by profound defects in T-cell function. Programmed death-1 is a receptor involved in tumor-mediated immunosuppression through binding of the PD-L1 ligand. Multiparametric flow cytometry and immunohistochemistry were
Davide Brusa, Sara Serra, Marta Coscia, Davide Rossi, Giovanni D’Arena, Luca Laurenti, Ozren Jaksic, Giorgio Fedele, Giorgio Inghirami, Gianluca Gaidano, Fabio Malavasi, Silvia Deaglio   +11 more
doaj   +1 more source

METTL7A Downregulation Drives SLC1A5‐Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8+ T Cell Immunity in Gastric Cancer

Advanced Science, EarlyView.
GC cells enhance glutamine accumulation by upregulating SLC1A5 expression. This upregulation not only boosts GC cell proliferation, but also outcompetes CD8+ T cells for glutamine and suppresses their antitumor immunity. Mechanistically, METTL7A deficiency in GC induces SLC1A5 overexpression via an m6A‐dependent pathway and N‐glycosylation ...
Mingjun Sun, Shuwei Dang, Dazhi Zhou, Lixian Ding, Xun Sun, Wei Suo, Jirui Niu, Qingzhu Yang, Zhicheng Zhang, Yanyan Sun, Jinxing Li, Zhongsheng Chen, Tao Ban, Yingji Wang, Tianzhu Li, Ming Liu, Guodong Li   +16 more
wiley   +1 more source

The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy

Haematologica, 2014
Biologists and clinicians agree that the B-cell receptor influences the behavior of chronic lymphocytic leukemia, and promising new drugs are aimed at receptor-associated kinases.
Graham Packham, Serge Krysov, Alex Allen, Natalia Savelyeva, Andrew J. Steele, Francesco Forconi, Freda K. Stevenson   +6 more
doaj   +1 more source